The anandamide membrane transporter inhibitor, VDM-11, modulates sleep and c-Fos expression in the rat brain

Neuroscience

Volumn 157, Issue 1, 2008, Pages 1-11

  Murillo Rodriguez E ^a   Millan Aldaco D ^b   Di Marzo, V ^c   Drucker Colin R ^b  

^a UNIVERSIDAD AUTÓNOMA DE CAMPECHE   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c CNR   (Italy)

Author keywords

anandamide; CB1 cannabinoid receptor; delta power; rapid eye movement sleep; SR141716A

Indexed keywords

ANANDAMIDE; N (4 HYDROXY 2 METHYLPHENYL)ARACHIDONAMIDE; PROTEIN C FOS; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SLEEP WAKING CYCLE;

ANIMALS; ARACHIDONIC ACIDS; BRAIN CHEMISTRY; ELECTROENCEPHALOGRAPHY; GENE EXPRESSION REGULATION; GENES, FOS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENTRICULAR; MALE; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTORS, CANNABINOID; SLEEP; SLEEP STAGES;

EID: 54549121278     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2008.08.056     Document Type: Article

References (54)

1. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Makriyannis A., Khanolkar A., Layward L., Fezza F., Bisogno T., and Di Marzo V. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15 (2001) 300-302
2. Bandyopadhya R.S., Datta S., and Saha S. Activation of pedunculopontine tegmental protein kinase A: a mechanism for rapid eye movement sleep generation in the freely moving rat. J Neurosci 26 (2006) 8931-8942
3. Battista N., Fezza F., Finazzi-Agro A., and Maccarrone M. The endocannabinoid system in neurodegeneration. Ital J Biochem 55 (2006) 283-289
4. Bifulco M., Laezza C., Valenti M., Ligresti A., Portella G., and Di Marzo V. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 18 (2004) 1606-1608
5. Bisogno T., Melck D., De Petrocellis L., Bobrov M., Gretskaya N.M., Bezuglov V.V., Sitachitta N., Gerwick W.H., and Di Marzo V. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Commun 248 (1998) 515-522
6. Bortolato M., Campolongo P., Mangieri R.A., Scattoni M.L., Frau R., Trezza V., La Rana G., Russo R., Calignano A., Gessa G.L., Cuomo V., and Piomelli D. Anxiolytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 12 (2006) 2652-2659
7. Corsi-Cabrera M., Pérez-Garci E., Del Rio-Portilla Y., Ugalde E., and Guevara M.A. EEG bands during wakefulness, slow-wave, and paradoxical sleep as a result of principal component analysis in the rat. Sleep 24 (2001) 374-380
8. Cristino L., de Petrocellis L., Pryce G., Baker D., Guglielmotti V., and Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139 (2006) 1405-1415
9. D'Argenio G., Valenti M., Scaglione G., Cosenza V., Sorrentini I., and Di Marzo V. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 20 (2006) 568-570
10. de Lago E., Fernández-Ruiz J., Ortega-Gutiérrez S., Cabranes A., Pryce G., Baker D., López-Rodríguez M., and Ramos J.A. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders. Eur Neuropsychopharmacol 16 (2006) 7-18
11. de Lago E., Ligresti A., Ortar G., Morera E., Cabranes A., Pryce G., Bifulco M., Baker D., Fernandez-Ruiz J., and Di Marzo V. In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. Eur J Pharmacol 484 (2004) 249-257
12. de Lago E., Petrosino S., Valenti M., Morera E., Ortega-Gutierrez S., Fernandez-Ruiz J., and Di Marzo V. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochem Pharmacol 70 (2005) 446-452
13. De Petrocellis L., Bisogno T., Maccarrone M., Davis J.B., Finazzi-Agro A., and Di Marzo V. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem 16 (2001) 12856-12863
14. Di Marzo V., De Petrocellis L., Fezza F., Ligresti A., and Bisogno T. Anandamide receptors. Prostaglandis Leukot Essent Fatty Acids 66 (2002) 377-391
15. Di Marzo V., and Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipid 2 (2007) 129-140
16. Gubellini P., Picconi B., Bari M., Battista N., Calabresi P., Centonze D., Bernardi G., Finazzi-Agrò A., Lopez-Rodriguez M.L., Viso A., Ortega-Gutierrez S., Lastres-Becker I., Gonzalez S., Fernandez-Ruiz J., and Ramos J.A. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. J Med Chem 26 (2001) 4505-4508
17. Hillard C.J., Shi L., Tuniki V.R., Falck J.R., and Campbell W.B. Studies of anandamide accumulation inhibitors in cerebellar granule neurons: comparison to inhibition of fatty acid amide hydrolase. J Mol Neurosci 33 (2007) 18-24
18. Izzo A.A., Capasso F., Costagliola A., Bisogno T., Marsicano G., Ligresti A., Matias I., Capasso R., Pinto L., Borrelli F., Cecio A., Lutz B., Mascolo N., and Di Marzo V. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 125 (2003) 765-774
19. Ligresti A., Cascio M.G., and Di Marzo V. Endocannabinoid metabolic pathways and enzymes. Curr Drug Targets CNS Neurol Dis 4 (2005) 615-623
20. Llinás R.R., and Steriade M. Bursting of thalamic neurons and states of vigilance. J Neurophysiol 95 (2006) 3297-3308
21. López-Rodríguez M.L., Viso A., Ortega-Gutiérrez S., Fowler C.J., Tiger G., de Lago E., Fernández-Ruiz J., and Ramos J.A. Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors. Eur J Med Chem 38 (2003) 403-412
22. Losier B.J., and Semba K. Dual projections of single cholinergic and aminergic brainstem neurons to the thalamus and basal forebrain in the rat. Brain Res 604 (1993) 41-52
23. Maccarrone M., Battista N., and Centonze D. The endocannabinoid pathway in Huntington's disease: A comparison with other neurodegenerative diseases. Prog Neurobiol 81 (2007) 349-379
24. Martínez-Vargas M., Murillo-Rodríguez E., González-Rivera R., Landa A., Méndez-Díaz M., Prospro-García O., and Navarro L. Sleep modulates cannabinoid receptor 1 expression in the pons of rats. Neuroscience 117 (2003) 197-201
25. Moldrich G., and Wenger T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study. Peptides 21 (2000) 1735-1742
26. Moore S.A., Nomikos G.G., Dickason-Chesterfield A.K., Schober D.A., Schaus J.M., Ying B.P., Xu Y.C., Phebus L., Simmons R.M., Li D., Iyengar S., and Felder C.C. Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc Natl Acad Sci U S A 102 (2005) 17852-17857
27. Moreira F.A., Aguiar D.C., and Guimarães F.S. Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology 3 (2007) 958-965
28. Murillo-Rodríguez E., Blanco-Centurión C., Sánchez C., Piomelli D., and Shiromani P.J. Anandamide enhances extracellular levels of adenosine and induces sleep: An in vivo microdialysis study. Sleep 26 (2003) 943-997
29. Murillo-Rodríguez E., Cabeza R., Méndez-Díaz M., Navarro L., and Prospéro-García O. Anandamide-induced sleep is blocked by SR141716A, a CB1 receptor antagonist and by U73122, a phospholipase C inhibitor. Neuroreport 12 (2001) 2131-2136
30. Murillo-Rodríguez E., Désarnaud F., and Prospéro-García O. Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. Life Sci 1 (2006) 30-37
31. Murillo-Rodríguez E., Millán-Aldaco D., Palomero-Rivero M., Mechoulam R., and Drucker-Colín R. Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett 580 (2006) 4337-4345
32. Murillo-Rodríguez E., Sánchez-Alavez M., Navarro L., Martínez-González D., Drucker-Colín R., and Prospéro-García O. Anandamide modulates sleep and memory in rats. Brain Res 812 (1998) 270-274
33. Murillo-Rodríguez E., Vázquez E., Millán-Aldaco D., Palomero-Rivero M., and Drucker-Colín R. Effects of the fatty acid amide hydrolase inhibitor URB597 on the sleep-wake cycle, c-Fos expression and dopamine levels of the rat. Eur J Pharmacol 562 (2007) 82-91
34. Murillo-Rodríguez E., Vázquez-Luis E., Millán-Aldaco D., Haro R., and Drucker-Colín R. Promoting of wakefulness by administrations of modafinil into anterior hypothalamus and into the pedunculopontine tegmental nucleus in rats. Neurosci Lett 436 (2008) 283-287
35. Oddi S., Bari M., Battista N., Barsacchi D., Cozzani I., and Maccarrone M. Confocal microscopy and biochemical analysis reveal spatial and functional separation between anandamide uptake and hydrolysis in human keratinocytes. Cell Mol Life Sci 62 (2005) 386-395
36. Ong W.Y., and Mackie K. A light and electron microscopic study of the CB1 cannabinoid receptor in primate brain. Neuroscience 92 (1999) 1177-1191
37. Ortar G., Ligresti A., De Petrocellis L., Morera E., and Di Marzo V. Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochem Pharmacol 65 (2003) 1473-1481
38. Ortega-Gutiérrez S. Therapeutic perspectives of inhibitors of endocannabinoid degradation. Curr Drug Targets CNS Neurol Dis 4 (2005) 697-708
39. Oz M. Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. Pharmacol Ther 1 (2006) 114-144
40. Patel S., Cravatt B.F., and Hillard C.J. Synergistic interactions between cannabinoids and environmental stress in the activation of the central amygdala. Neuropsychopharmacology 3 (2005) 497-507
41. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates (1986), Academic Press, New York
42. Pettit D.A., Harrison M.P., Olson J.M., Spencer R.F., and Cabral G.A. Immunohistochemical localization of the neural cannabinoid receptor in rat brain. J Neurosci Res 51 (1998) 391-402
43. Piomelli D. The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 6 (2005) 672-679
44. Rinaldi-Carmona M., Barth F., Héaulme M., Alonso R., Shire D., Congy C., Soubrié P., Brelière J.C., and Le Fur G. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 56 (1995) 1941-1947
45. Santucci V., Storme J.J., Soubrié P., and Le Fur G. Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR141716A in rats as assessed by electroencephalographic spectral and sleep-waking analysis. Life Sci 58 (1996) PL103-PL110
46. Saper C.B., Scammell T.E., and Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 437 (2005) 1257-1263
47. Semba K., and Fibiger H.C. Afferent connections of the laterodorsal and the pedunculopontine tegmental nuclei in the rat: a retro- and antero-grade transport and immunohistochemical study. J Comp Neurol 323 (1992) 387-410
48. Soria-Gómez E., Matias I., Rueda-Orozco P.E., Cisneros M., Petrosino S., Navarro L., Di Marzo V., and Prospéro-García O. Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. Br J Pharmacol 151 (2007) 1109-1116
49. Steininger T.L., Gong H., McGinty D., and Szymusiak R. Subregional organization of preoptic area/anterior hypothalamic projections to arousal-related monoaminergic cell groups. J Comp Neurol 429 (2001) 638-653
50. Szymusiak R., Gvilia I., and McGinty D. Hypothalamic control of sleep. Sleep Med 8 (2007) 291-301
51. Ulloor J., Mavanji V., Saha S., Siwek D.F., and Datta S. Spontaneous REM sleep is modulated by the activation of the pedunculopontine tegmental GABAB receptors in the freely moving rat. J Neurophysiol 91 (2004) 1822-1831
52. Valenti M., Vigano D., Casico M.G., Rubino T., Steardo L., Parolaro D., and Di Marzo V. Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. Cell Mol Life Sci 8 (2004) 945-950
53. van der Stelt M., Mazzola C., Esposito G., Matias I., Petrosino S., De Filippis D., Micale V., Steardo L., Drago F., Iuvone T., and Di Marzo V. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 12 (2006) 1410-1424
54. Vandevoorde S., and Fowler C.J. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate. Br J Pharmacol 145 (2005) 885-893